Market
Most Common Side Effect of ENHERTU® in HER2-low Patients by 2025?
2
Resolution / Starting Odds
Nausea • 25%
Fatigue • 25%
Neutropenia • 25%
Other • 25%
Published clinical studies and patient reports
Story
FDA Approves ENHERTU® for HER2-Low Breast Cancer, Showing 36% Risk Reduction and Hazard Ratio of 0.64
Jan 28, 2025, 12:04 AM
The U.S. Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer. This approval is specifically for patients who have experienced disease progression following one or more endocrine therapies. Clinical data indicates that ENHERTU® demonstrated a 36% reduction in the risk of disease progression or death compared to chemotherapy, with a hazard ratio of 0.64 (95% confidence interval: 0.54-0.76; p<0.0001) in a trial involving chemotherapy-naïve patients with HER2-low or HER2-ultralow metastatic breast cancer. The approval marks a significant advancement in treatment options for this patient population, which previously had limited therapeutic alternatives.
View original story
Similar markets
More than 4 • 25%
3 to 4 • 25%
1 to 2 • 25%
None • 25%
Enhertu higher ORR • 25%
Same ORR • 25%
VIR-5818 higher ORR • 25%
Data not available • 25%
Pancreatitis • 25%
Other • 25%
Arthritis • 25%
Kidney Issues • 25%
Less than 10% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Severe side effects • 25%
Mild side effects • 25%
Moderate side effects • 25%
No major side effects • 25%
Significant survival improvement • 25%
Trial stopped early for safety concerns • 25%
Trial stopped early for efficacy • 25%
No significant survival improvement • 25%
No major side effects • 25%
Brain swelling • 25%
Bleeding • 25%
Other • 25%
No • 50%
Yes • 50%
Less than 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
More than 70% • 25%